anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Currently, riociguat is the only drug approved in Europe and US for the treatment of non-operable CTEPH. However, medical therapy with riociguat does not address obstructive lesions. In this sense, another treatment option, balloon pulmonary angioplasty (BPA), began recently to gain widespread interest after development in several centers. This procedure uses the standard balloon angioplasty technique to dilate selected pulmonary arteries. The main aim is to reopen vessels occluded by webs and bands. Several teams, mainly from Japan, have reported their experiences with BPA for the treatment of non-operable CTEPH and demonstrated impressive decrease in pulmonary vascular resistance and improvement in functional status and exercise capacity with an acceptable procedure-related risk. Although BPA has never been prospectively evaluated, most of the leading CTEPH centers worldwide have currently added BPA to their therapeutic options. However, no randomized controlled trial comparing safety and efficacy of medical therapy with riociguat versus pulmonary balloon angioplasty has been performed so far. Therefore, the respective places of medical treatment and of BPA in the management of inoperable patients with CTEPH need to be further evaluated.

An ancillary study will evaluate the efficacy and safety of employment of two sequentially used treatments at 12 months. The studied population is that of the study RACE. The patient follow-up period will be extended by 6 months, its duration of participation will be in total of 13 months. The exams will be the same as those of the V3 of the RACE study.
PURPOSE: To provide an affixing tape which does not adversely affect the human body and is strong to wetting with water. CONSTITUTION: A tape base 2 consisting of woven fabric of cotton, etc., having air permeability and hygroscopicity is subjected to a water repelling treatment by a polyurethane. An affixing layer 3 of water-soluble glue which hardly affects the skin as an affixing agent is adhered in a planar from to one surface side of this tape base 2. For example, copper foil pieces 4 and aluminum foil pieces 5 are dispersedly arranged on the affixing layer 3 and are exposed on the front surface. Both of the affixing material and the water repelling material contain an isocyanate. The affixing agent is polymerized with the water repelling agent of the tape base 2 near the boundary by the polymerizing agent incorporated into the affixing agent and, therefore, the adhesion property of the affixing layer 3 to the tape base 2 is enhanced.  Since the tape base 2 is subjected to the water repelling treatment, the tape base 2 is not moistened even if a user has more than needed sweat or the tape is splashed with water from the outside in a bath and, therefore, such thing that the more than needed water is included in the affixing layer 3 does not arise any more and the peeling of the affixing tape 1 is prevented.
PURPOSE: A topoisomerase 2 alpha-derived tumor antigen protein, gene, or peptide is provided to induce tumor cell-specific cytotoxic immune response. CONSTITUTION: A tumor antigen contains topoisomerase 2 alpha C-terminal-derived protein fragment, peptides, or derivative thereof. The tumor antigen is recognized by cytotoxic T lymphocytes by binding with MHC class I or II antigen. The topoisomerase 2 alpha is derived from human body or mouse. The protein fragment contains an amino acid sequence of sequence number 2 or 4. The peptide contaisn an amino acid sequence of sequence number 5. A composition for preventing or treating tumor contains the tumor antigen or a gene encoding the same. A composition for preventing or treating tumor contains antigen-presenting cells.
The present invention relates to a combination of the cannabidiol (CBD) and an antibiotic for use in the treatment of bacterial infection. The bacterial infection may be caused by a gram positive bacterium or a gram negative bacterium. The antibiotic may be colistin, rifampicin, erythromycin, kanamycin, or vancomycin. The CBD may be obtained from a highly purified extract of cannabis comprising at least 95 % CBD and said extract may comprise up to 0.1 % tetrahydrocannabinol (THC). Alternatively, the CBD may be synthetic. The dose of CBD may be between 0.1 and 1000 mg/kg/day.
OBJECTIVE: Research indicates that long noncoding RNAs (lncRNAs) contribute significantly to fibrotic diseases. Although lncRNAs may play a role in hypertrophic scars after burns, its mechanisms remain poorly understood.
METHODS: Using chip technology, we compared the lncRNA expression profiles of burn patients and healthy controls (HCs). Microarray results were examined by quantitative reverse-transcription polymerase chain reaction (RT-PCR) to verify their reliability. The biological functions of differentially expressed mRNAs and the relationships between genes and signaling pathways were investigated by Gene Ontology (GO) and pathway analyses, respectively.
RESULTS: In contrast with HCs, it was found that 2738 lncRNAs (1628 upregulated) and 2166 mRNAs (1395 upregulated) were differentially expressed in hypertrophic scars after burn. Results from RT-PCR were consistent with those from microarray. GO and pathway analyses revealed that the differentially expressed mRNAs are mainly associated with processes related to cytokine secretion in the immune system, notch signaling, and MAPK signaling.
CONCLUSION: The lncRNA expression profiles of hypertrophic scars after burn changed significantly compared with HCs. It was believed that the transcripts could be used as potential targets for inhibiting abnormal scar formation in burn patients.
A medical fluid delivery system including analytics for managing patient engagement and treatment compliance is disclosed. In an example, an interface device receives treatment data from a dialysis machine for a patient undergoing dialysis. An analytics processor determines dialysis treatment parameter values by comparing the treatment data to a record of a prescribed therapy or program. The dialysis treatment parameter values may include a lost treatment time parameter value, a lost dwell time parameter value, and/or a completed treatment days parameter value. The analytics processor causes the dialysis treatment parameter values to be displayed within a user interface on a clinician device. The dialysis treatment parameter values provide an indication as to how well the patient is complying with the prescribed therapy or program, and may be used by a clinician to help a patient improve compliance if needed.
Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at next visit. There will be a minimum period of 12 hours between drug interventions to ensure adequate drug wash-out. Subjects will also undergo pulmonary function testing and electrocardiogram.
Self-affirmation, a process by which individuals reflect on cherished personal values is a potent means of augmenting the effectiveness of threatening health communications. Individuals tend to be defensive against information suggesting their behavior puts them at risk for disease or negative health. Previous evidence suggests that self-affirmation may reduce defensiveness to threatening health information, increasing openness to the message and resulting in increased disease risk perceptions, disease-related worry, intentions to engage in preventive behavior, and actual behavioral change. Understanding the mechanisms that explain these robust effects would yield evidence important for dissemination, including ways to refine self-affirmation interventions and make them more potent, which could change the ways that public health messages are constructed. Thus, we aim to elucidate potential mechanisms underlying the effectiveness of self-affirmation, including self-activation, general affirmation, and domain-specific affirmation. In study 1, female human subjects will be randomly assigned to one of eleven affirmation or self- activation conditions. Following the affirmation or activation task, subjects will read about the documented link between alcohol and breast cancer. Finally, they will be asked a series of questions about their intentions to reduce drinking, their perceived risk of breast cancer, and their worry about breast cancer. Study 2 will replicate study 1, but in a different behavioral domain (physical activity) and a different sample (both males and females who do not meet physical activity recommendations). Study 3 will extend Studies 1 and 2 by examining whether the most effective self-affirmations identified in these studies produce short-term increases in fruit and vegetable consumption. Drawing on previous research, we hypothesize these inductions will be effective to the degree that they involve a self-affirmation, but will not be effective if they involve only other-affirmation or self-activation.
Trigger finger (TF) is one of the most prevalent causes of hand disability and is a common cause of referral to orthopedic clinics. Trigger finger is tenosynovitis of the flexor sheaths that typically occurs in the 4th finger and thumb as a result of repetitive use. The incidence of TF is 28:100,000 per year or lifetime risk of 2.6% in the general population. It has the highest incidence being between 52 and 62 years more in women (75%). Thumb and fourth digit (ring finger) are the most commonly affected fingers.

Dry needling (DN) is a relatively new technique used by physical therapists to treat myofascial trigger points (MTrPs) and various pain syndromes. Dry needling is defined as a "skilled intervention using a thin filiform needle to penetrate the skin that stimulates myofascial TrPs, muscles, and connective tissue for the treatment of musculoskeletal pain disorders. DN has analgesic and anti-inflammatory effects, it is commonly used to relieve pain and reduce inflammation.
System, method and computer readable medium that assess characteristics of an embryo by processing video image data of the embryo. Video is obtained, typically from third parties, of a target embryo. The video has frame speed of two frames per second, or faster and includes image data representing morphokinetic movement of the embryo. The image data is processed using a trained machine learning model that assesses embryo characteristics. The video has a duration of ten minutes or less. The assessment can be a prediction of a likelihood the embryo is viable and/or will produce a pregnancy upon transfer into a recipient. Further, the assessment can predict a likelihood the embryo will: (1) produce offspring having a specific sex; (2) embody a genetic anomaly; (3) perpetuate desired traits in produced offspring and/or (4) produce undesired characteristics in produced offspring.
A new therapy for AML is necessary because, although there are several treatment options for patients with AML, these treatments are very toxic and not available to all AML patients or only useful for acute promyelocytic leukemia (APL). Also, there is essentially no treatment for patients with refractory or relapsed AML outside of bone marrow transplant. Accordingly, there is a great medical need for a safe and effective therapy for AML, especially refractory and relapsed AML. Also, although hypomethylating agents have been found to be effective against MDS, these agents are toxic. Furthermore, after relapsing from a hypomethylating agent, there is no treatment for this disease.

A nearly completed clinical trial of CPI-613 (Cornerstone Study# CL-CPI-613-009 or Wake Forest Study# CCCWFU 29109, under IND# 107,800) shows that CPI-613 is well tolerated at doses as high as 3,000 mg/m2. Results from this nearly completed trial also suggest that CPI- 613 may be effective against refractory and relapsed AML, as well as against MDS that is relapsed from a hypomethylating agent. Therefore, CPI-613 may be a suitable treatment option for refractory/relapsed AML and MDS relapsed from a hypomethylating agent. The promising preliminary efficacy data from Study# CL-CPI-613-009 (Wake Forest Study# CCCWFU 29109, under IND# 107,800) is the basis on which Cornerstone is conducting the current Phase 2a trial to further assess the efficacy of CPI-613 against these diseases.
Begin MULPLETA dosing 8-14 days prior to a scheduled procedure. 

Patients should undergo their procedure 2-8 days after the last dose.

The recommended dosage of MULPLETA is 3 mg taken orally once daily with or without food for 7 days. In the case of a missed dose of MULPLETA, patients should take the missed dose as soon as possible on the same day and return to the normal schedule the following day.

MULPLETA has been investigated only as a single 7-day once daily dosing regimen in clinical trials in patients with chronic liver disease [see Clinical Studies (14)]. MULPLETA should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts.
AIMS: Pulmonary vein isolation (PVI) is increasingly performed in patients with atrial fibrillation (AF). Both AF phenotype and left atrial (LA) volume have been shown to influence ablation outcome. The inter-relationship of the two is incompletely understood. We aimed to investigate the impact of AF phenotype vs. LA volume on outcome after PVI.
METHODS AND RESULTS: In a retrospective analysis of a prospective registry of patients undergoing a first PVI, the association of AF phenotype and LA volume index (LAVI) was assessed as well as their impact on AF recurrence during follow-up. Overall, 476 patients were enrolled (median age 63 years, 29% females, 65.8% paroxysmal AF). Obesity, hypertension, chronic kidney disease, and heart failure were all significantly more frequent in persistent AF. After 1 year, single-procedure, freedom from arrhythmia recurrence was 61.5%. Patients with paroxysmal AF had better outcomes compared with patients with persistent AF (65.6 vs. 52.7%, P = 0.003), as had patients with no/mild vs. moderate/severe LA dilation (LAVI <42 mL/m2 67.1% vs. LAVI ≥42 mL/m2 53%, P < 0.001). The combination of both parameters refined prediction of 1-year recurrence (P < 0.001). After adjustment for additional clinical risk factors in multivariable Cox proportional hazard analysis, both AF phenotype and LAVI ≥42 mL/m2 contributed significantly towards the prediction of 1-year recurrence.
CONCLUSION: Atrial fibrillation phenotype and LA volume are independent predictors of outcome after PVI. Persistent AF with no/mild LA dilation has a similar risk of recurrence as paroxysmal AF with a moderate/severe LA dilation and should be given similar priority for ablation.
BACKGROUND: Our previous study demonstrated that microRNA-409-5p (miR-409-5p) and its target ubiquitin-specific protease 7 (USP7) were involved in hypoxia-induced cardiomyocyte injury and ischemic left ventricular remodeling (LVR) in rats. This study aimed to probe into the relationship between plasma miR-409-5p and USP7 levels and LVR and dysfunction in patients with acute myocardial infarction (AMI).
METHODS: Sixty patients with acute myocardial infarction (AMI) and 60 cases with chronic coronary syndrome (CCS) were enrolled. The clinical characteristics, echocardiographic/serum parameters of LVR, and circulating miR-409-5p and USP7 mRNA levels between the two groups and between admission and 6 weeks after discharge were compared. The correlations between circulating miR-409-5p/USP7 levels and serum/echocardiographic parameters were analyzed.
RESULTS: The demographic characteristics of the AMI group and CCS group were comparable. Patients with AMI admitted to the study displayed significantly higher levels of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) and growth stimulation expressed gene 2 (ST2), along with a greater left ventricular end-systolic volume (LVESV). Conversely, their left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), and global radial strain (GRS) were significantly lower compared to patients with CCS. These changes were normalized 6 weeks after discharge. Circulating miR-409-5p levels at admission were significantly decreased while circulating USP7 mRNA expression levels were significantly increased in patients with AMI compared with those with CCS (both P < 0.01). However, these changes were restored 6 weeks after discharge (both P < 0.01). Moreover, circulating miR-409-5p and USP7 mRNA levels showed varying correlations with GLS, GRS, LVESV, LVEF, and NT-proBNP in patients with AMI but not in those with CCS. Additionally, circulating miR-409-5p and USP7 levels predicted the incidence of LVR and major adverse cardiovascular events (MACE) after AMI.
CONCLUSION: Serum miR-409-5p and USP7 may influence the occurrence and evolution of LVR and left ventricular dysfunction after AMI.
BACKGROUND: Venous thromboembolism (VTE) following revision total joint arthroplasty (TJA) poses significant risks despite prophylactic measures. The optimal VTE prophylaxis agent for revision TJA remains unclear. This study aimed to compare aspirin against various anticoagulant agents regarding efficacy and safety in preventing symptomatic VTE events after revision TJA.
METHODS: A retrospective analysis included 4,575 patients undergoing revision TJA between 2008 and 2020. Of these, 2,091 received aspirin, while 2,484 received other anticoagulants. Demographic, procedural, and outcome data were collected. Logistic regression models were used to identify predictors of symptomatic VTE.
RESULTS: The aspirin group showed a significantly lower incidence of symptomatic VTE compared to the other anticoagulant group (0.53 versus 2.54%, P < .001). Logistic regression confirmed a higher risk of VTE with other anticoagulants (odds ratio: 0.2 to 0.26, P < .001), while blood transfusion (odds ratio: 2.72, P = .001) were identified as risk factors.
CONCLUSIONS: This study demonstrated that aspirin is a viable and potentially safer option than other anticoagulants, exhibiting comparable efficacy in preventing VTE events in revision TJA. Balancing effectiveness and safety is crucial, considering patient-specific risk factors and bleeding tendencies. This large cohort study demonstrated that aspirin was associated with a more effective and safer VTE prophylaxis agent, compared to other anticoagulants, in patients undergoing revision TJA.
The efficacy of venlafaxine hydrochloride extended-release capsules as a treatment for Social Anxiety Disorder (SAD) was established in four double-blind, parallel-group, 12-week, multicenter, placebo-controlled, flexible-dose studies (studies 1 to 4) and one double-blind, parallel-group, 6-month, placebo-controlled, fixed/flexible-dose study, which included doses in a range of 75 to 225 mg per day in adult outpatients meeting DSM-IV criteria for SAD (study 5).

In these five studies, venlafaxine hydrochloride extended-release capsules were statistically significantly more effective than placebo on change from baseline to endpoint on the Liebowitz Social Anxiety Scale (LSAS) total score. There was no evidence for any greater effectiveness of the 150 to 225 mg per day group compared to the 75 mg per day group in the 6-month study.

Examination of subsets of the population studied did not reveal any differential responsiveness on the basis of gender. There was insufficient information to determine the effect of age or race on outcome in these studies.

SD=standard deviation; SE=standard error; LS Mean=least-squares mean; CI=confidence interval.
BACKGROUND: The objective of this systematic review is to analyze the influence of carbohydrate (CHO) intake on physical and technical aspects, glucose and muscle glycogen levels, fatigue, cognition, and gastrointestinal comfort involved in the performance of soccer players, as well as to examine whether there are any differences between men and women.
METHODS: A bibliographic search was conducted in PubMed, Web of Science, Scopus, and SportDiscus, resulting in 61 selected articles. The PRISMA recommendations and the Cochrane Handbook for Systematic Reviews guidelines were followed.
RESULTS: The results indicate that CHO intake before and during the match improves speed and the number of sprints, attenuates the decrease in shooting accuracy and speed, increases time to fatigue, and enhances cognitive function. There is no consensus on passing, dribbling, jumping, or agility improvements. Glucose levels drop during the first 15 min of the second half without affecting performance.
CONCLUSIONS: It is recommended that players ingest 6-8 g/kg/d of CHO the day before, a meal with 1-3 g/kg 3-4 h before, and 30-60 g/h during the match. Muscle glycogen drops drastically at the end of the match, remaining low at 48 h. Hence, 1-1.5 g/kg/h is recommended during the first 4 h, starting from the first 20 min. Female soccer players have a similar physical demand to men, and energy availability is low, especially in the post-match periods, as they underestimate their energy expenditure and do not consume enough CHO. Therefore, the recommended guidelines should be followed, individualized, and periodized according to each athlete's energy needs.
The hormones oxytocin and vasopressin are extracted from the posterior lobe of the pituitary by treating the said lobe, or a dry extract thereof, with a dilute (2 per cent or less) aqueous solution of an organic acid, e.g. acetic, propionic or tartaric acid, absorbing the hormones on activated silica, and then treating the absorbent with a dilute aqueous solution of an organic acid, preferably the same as as previously used, to obtain an eluate containing the oxytocin and a residue containing the vasopressin. For the extraction of the former, the eluate is preferably first freed from ferrous ions present by treatment with a-di-pyridyl, cupferron, sulphocyanides, oxyquinolines, &c. which form non-ionized complexes, then concentrated in carbon dioxide at 5 DEG C or lower, and the a-dipyridyl extracted with ether; then, it is preferably extracted with secondary octanol or chloroform to eliminate lipoids and pigments; finally, after being made slightly alkaline with ammonia, it is extracted with n-butanol saturated with water.  Water is eliminated from the extract by freezing at -60 DEG C, then ammonia by vacuum treatment in a current of nitrogen, and finally the butanol by distillation at 25-30 DEG C in nitrogen at 1/10-1/50mm. pressure. The concentrate is extracted with 0.1 per cent acetic acid, the extracted solution washed with chloroform, and the latter removed by bubbling in nitrogen.  The solution is finally treated with a bacteriostatic, e.g. chloretone.  For the extraction of the vasopressin, the silica is rendered alkaline, below pH 10, by ammonia, and then treated with a solution of an electrolyte, e.g. sodium chloride or sulphate containing an organic acid and preferably a surface active agent to produce a solution of the hormone.  The electrolytes are precipitated by ethyl alcohol which is removed by distillation. The solution of vasopressin may be further purified by treatment with a water-insoluble solution of an aromatic acid, e.g. salicylic, in a water-miscible solvent, e.g. acetone.  The acid precipitated absorbs the vasopressin, and it is then extracted by a mixture of water and ether, the hormone passing to the aqueous phase. The solution may be purified by extraction with n-butanol saturated with water and containing 1 per cent salicylic acid. The activated silica employed may be obtained by the process disclosed in Specification 714,378, [Group III].